Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.TA)

TEVA.TA on Tel Aviv Stock Exchange

7,240.00ILa
13 Dec 2018
Change (% chg)

77.00 (+1.07%)
Prev Close
7,163.00
Open
7,150.00
Day's High
7,260.00
Day's Low
7,101.00
Volume
707,072
Avg. Vol
679,282
52-wk High
9,475.00
52-wk Low
5,400.00

Chart for

About

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic... (more)

Overall

Beta: 1.51
Market Cap(Mil.): ₪82,578.76
Shares Outstanding(Mil.): 1,018.73
Dividend: --
Yield (%): 2.27

Financials

  TEVA.TA Industry Sector
P/E (TTM): -- 29.45 30.88
EPS (TTM): -44.55 -- --
ROI: -20.54 14.34 13.80
ROE: -62.22 15.85 15.29

Class certified in Lamictal antitrust case against GSK, Teva

Purchasers of GlaxoSmithKline PLC's anti-seizure drug Lamictal have won class certification for an antitrust lawsuit claiming the drugmaker conspired with Teva Pharmaceutical Industries Ltd to delay the latter's generic version.

Dec 13 2018

Teva Pharm to move headquarters to Tel Aviv

JERUSALEM, Dec 13 Israel-based Teva Pharmaceutical Industries said on Thursday it was moving its headquarters to Tel Aviv as part of a global restructuring.

Dec 13 2018

Teva to recall certain blood pressure medicine in U.S

Teva Pharmaceutical Industries Ltd is recalling certain combinations of blood pressure drug valsartan in the United States following the detection of a probable cancer-causing impurity, the latest global recall of the medicine.

Nov 27 2018

Teva to recall certain blood pressure medicine in U.S.

Nov 27 Teva Pharmaceutical Industries Ltd is recalling certain combinations of blood pressure drug valsartan in the United States following the detection of a probable cancer-causing impurity, the latest global recall of the medicine.

Nov 27 2018

Teva prices EpiPen generic at $300, same price as Mylan generic

Teva Pharmaceutical Industries Ltd said on Tuesday it launched its generic version of Mylan NV's EpiPen at the wholesale price of $300 for a pack of two auto-injectors - the same price as Mylan's generic version of the emergency allergy shot.

Nov 27 2018

UPDATE 2-Teva prices EpiPen generic at $300, same price as Mylan generic

Nov 27 Teva Pharmaceutical Industries Ltd said on Tuesday it launched its generic version of Mylan NV's EpiPen at the wholesale price of $300 for a pack of two auto-injectors - the same price as Mylan's generic version of the emergency allergy shot.

Nov 27 2018

Teva prices EpiPen generic at $300

Nov 27 Teva Pharmaceutical Industries Ltd said on Tuesday its generic version of Mylan NV's EpiPen will have a wholesale price of $300.

Nov 27 2018

Teva Pharm raises 2018 profit outlook, sees strong migraine drug launch

TEL AVIV Teva Pharmaceutical Industries raised its 2018 earnings outlook, said it was seeing "a very strong launch" for its long-awaited migraine treatment Ajovy and expects to launch generic EpiPen in the fourth quarter.

Nov 01 2018

Teva Pharm Q3 profit tops estimates, raises 2018 profit forecast

TEL AVIV, Nov 1 Israel's heavily indebted Teva Pharmaceutical Industries reported a smaller-than-expected drop in third-quarter profit on Thursday and raised its earnings outlook for 2018.

Nov 01 2018

REFILE-BRIEF-Harbin Pharmaceutical Signs Agreement With Israel's Teva Pharmaceutical Industries

* SAYS IT SIGNS AUTHORIZATION AND DISTRIBUTION AGREEMENT WITH ISRAEL'S TEVA PHARMACEUTICAL INDUSTRIES, EXPECTS INVESTMENT OF ABOUT 160 MILLION YUAN Source text in Chinese: https://bit.ly/2PdGwJL Further company coverage: (Reporting by Hong Kong newsroom)

Oct 22 2018

Earnings vs. Estimates